These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1856127)

  • 21. In vitro activity of lomefloxacin as compared with ciprofloxacin.
    Inderlied CB; Lancero MG; Bermudez LM; Young LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):17S-20S. PubMed ID: 2791493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates.
    Wright DN; Saxon B; Matsen JM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):7S-11S. PubMed ID: 2791501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.
    Jones RN
    Am J Med; 1992 Apr; 92(4A):52S-57S. PubMed ID: 1316072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to quinolones in pathogens causing urinary tract infections.
    Kapoor H; Aggarwal P
    J Commun Dis; 1997 Sep; 29(3):263-7. PubMed ID: 9465532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The serum bactericidal activity of domestic fleroxacin and lomefloxacin].
    Zhao M; Jiang S; Wang R
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):98-100. PubMed ID: 11798634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro sensitivities of urinary tract pathogens to lomefloxacin and five other antimicrobial agents.
    Peddie BA
    N Z Med J; 1989 Jun; 102(869):298. PubMed ID: 2733911
    [No Abstract]   [Full Text] [Related]  

  • 27. [Bactericidal action of lomefloxacin a new pyridonecarboxylic acid derivative].
    Koikeda S; Okabe H; Shibata H; Hase T; Nakanishi N; Okezaki E; Kato H; Masamune Y
    Jpn J Antibiot; 1989 Jan; 42(1):193-9. PubMed ID: 2468799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
    Qadri SM; Lee GC; Ellis ME
    Chemotherapy; 1991; 37(3):166-74. PubMed ID: 1889304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lomefloxacin-induced modification of the kinetics of growth of gram-negative bacteria and susceptibility to phagocytic killing by human neutrophils.
    Pruul H; McDonald PJ
    J Antimicrob Chemother; 1990 Jan; 25(1):91-101. PubMed ID: 2108116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Studies of lomefloxacin in biliary tract infections].
    Ono Y; Kunii O
    Jpn J Antibiot; 1989 Apr; 42(4):1017-24. PubMed ID: 2769934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
    Brothers AM; Gibbs PS; Wooley RE
    Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lomefloxacin disc susceptibility criteria--a reappraisal.
    Smith JM; Hashmi ZS
    J Antimicrob Chemother; 1990 Jul; 26(1):152-3. PubMed ID: 2211438
    [No Abstract]   [Full Text] [Related]  

  • 34. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS; Talboys CA; Roberts AP
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antibacterial activity of lomefloxacin in the urine during the 4 days following a single 400 mg oral dose].
    Guibert J; Kitzis MD; Acar JF; Masquelier AM; Bellanger B
    Pathol Biol (Paris); 1989 May; 37(5):411-4. PubMed ID: 2506515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
    Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
    J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.
    Segreti J; Nelson JA; Goodman LJ; Kaplan RL; Trenholme GM
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1385-7. PubMed ID: 2802563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.